Overview

A Study to Assess How Much Drug Reaches the Blood When Given From Symbicort pMDI With Spacer Compared to That of Symbicort pMDI Without Spacer in Healthy Volunteers

Status:
Completed

Trial end date:
2017-03-27

Target enrollment:

Participant gender:

Summary

This study will be conducted to establish the relative bioavailability of budesonide and formoterol delivered via Symbicort pressurized metered-dose inhaler (pMDI) with and without a spacer device. Administration under each condition will occur with the concomitant administration of activated charcoal to estimate exposure through the lung and without activated charcoal to estimate total systemic exposure.

Phase:

Phase 1

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Parexel

Treatments:

Budesonide, Formoterol Fumarate Drug Combination
Charcoal